Patents by Inventor James RUSH

James RUSH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
    Patent number: 12435150
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: October 7, 2025
    Assignee: NOVARTIS AG
    Inventors: Pascal Espie, Christian Loesche, Lukas Roth, James Rush, Grazyna Wieczorek
  • Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
    Publication number: 20250206833
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating Sjögren's syndrome, by employing anti-CD40 antibodies.
    Type: Application
    Filed: July 26, 2024
    Publication date: June 26, 2025
    Inventors: Pascal ESPIE, Peter GERGELY, James RUSH
  • Methods For Prevention Of Graft Rejection In Xenotransplantation
    Publication number: 20250136706
    Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
    Type: Application
    Filed: October 2, 2024
    Publication date: May 1, 2025
    Applicants: Novartis AG, Emory University, The UAB Research Foundation
    Inventors: Guido JUNGE, James RUSH, Andrew B. ADAMS, Alfred Joseph TECTOR, III
  • ANTI-CD40 ANTIBODIES FOR USE IN PREVENTION OF GRAFT REJECTION
    Publication number: 20240287198
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.
    Type: Application
    Filed: September 1, 2023
    Publication date: August 29, 2024
    Inventors: Pascal ESPIE, Boerje HARALDSSON, James RUSH
  • Anti-CD40 antibodies for use in treatment of Sjögren's syndrome
    Patent number: 12065499
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating Sjögren's syndrome, by employing anti-CD40 antibodies.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: August 20, 2024
    Assignee: Novartis AG
    Inventors: Pascal Espie, Peter Gergely, James Rush
  • SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
    Publication number: 20240228640
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Application
    Filed: July 26, 2023
    Publication date: July 11, 2024
    Inventors: Christoph HEUSSER, James RUSH, Karen VINCENT
  • SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
    Publication number: 20240132606
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Application
    Filed: July 25, 2023
    Publication date: April 25, 2024
    Inventors: Christoph HEUSSER, James RUSH, Karen VINCENT
  • Anti-CD40 antibodies for use in prevention of graft rejection
    Patent number: 11780927
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: October 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Pascal Espie, Boerje Haraldsson, James Rush
  • Methods For Prevention Of Graft Rejection In Xenotransplantation
    Publication number: 20230203176
    Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
    Type: Application
    Filed: September 16, 2022
    Publication date: June 29, 2023
    Inventors: Guido JUNGE, James RUSH, Andrew B. ADAMS, Alfred Joseph TECTOR, III
  • SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
    Publication number: 20220204635
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Application
    Filed: August 16, 2021
    Publication date: June 30, 2022
    Inventors: Christoph HEUSSER, James RUSH, Karen VINCENT
  • ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS
    Publication number: 20220195061
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating T1DM, by employing anti-CD40 antibodies.
    Type: Application
    Filed: May 6, 2020
    Publication date: June 23, 2022
    Inventors: Pascal ESPIE, Allison GOLDFINE, Rainer MUSSMANN, James RUSH
  • ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS
    Publication number: 20220098315
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies.
    Type: Application
    Filed: January 9, 2020
    Publication date: March 31, 2022
    Inventors: Pascal ESPIE, Christian LOESCHE, Lukas ROTH, James RUSH, Grazyna WIECZOREK
  • Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies
    Patent number: 11124578
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 21, 2021
    Assignee: NOVARTIS AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • ANTI-CD40 ANTIBODIES FOR USE IN PREVENTION OF GRAFT REJECTION
    Publication number: 20210079107
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.
    Type: Application
    Filed: April 11, 2019
    Publication date: March 18, 2021
    Inventors: Pascal ESPIE, Boerje HARALDSSON, James RUSH
  • SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
    Publication number: 20200087409
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Application
    Filed: April 30, 2019
    Publication date: March 19, 2020
    Applicant: Novartis AG
    Inventors: Christoph HEUSSER, James RUSH, Karen VINCENT
  • Nucleic acids encoding silent Fc variants of anti-CD40 antibodies
    Patent number: 10323096
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: June 18, 2019
    Assignee: Novartis AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
    Publication number: 20190153111
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating Sjögren's syndrome, by employing anti-CD40 antibodies.
    Type: Application
    Filed: November 1, 2018
    Publication date: May 23, 2019
    Inventors: Pascal Espie, Peter Gergely, James Rush
  • SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
    Publication number: 20180118843
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 3, 2018
    Applicant: Novartis AG
    Inventors: Christoph HEUSSER, James RUSH, Karen VINCENT
  • Nucleic acids encoding silent Fc variants of anti-CD40 antibodies
    Patent number: 9828433
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: November 28, 2017
    Assignee: Novartis AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
    Publication number: 20170267772
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Applicant: Novartis AG
    Inventors: Christoph HEUSSER, James RUSH, Karen VINCENT